GlassScriptPhysician profile
Sedi Hadadian
NPI 1326295452
$4,438.60
in general payments reported to CMS, 2019-2025
22 companies · $1,297 in 2025
The $1,297 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.19 · 2020: $62.75 · 2021: $194 · 2022: $312 · 2023: $601 · 2024: $1,951 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,600 · Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,600.00 |
| Food and Beverage | $1,249.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $2,600.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $380.90 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $280.31 | 2023-2025 | |
| Astellas Pharma US INC | $166.54 | 2023-2025 | Veozah |
| Organon LLC | $150.73 | 2022-2024 | |
| Exeltis, USA INC. | $138.46 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $135.56 | 2021-2025 | Thinprep 2000 Processor, Aptima |
| Pfizer INC. | $92.54 | 2023 | |
| Sage Therapeutics, LLC | $74.73 | 2024-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $73.99 | 2021-2023 | Phexxi |
| Ethicon US, LLC | $60.48 | 2024 | Dermabond Prineo, Ethicon |
| Shield Therapeutics INC | $50.34 | 2023 | Accrufer |
| Sumitomo Pharma America, INC. | $49.42 | 2023-2025 | Gemtesa, Myfembree |
| Therapeuticsmd, INC. | $36.44 | 2020-2021 | |
| Daiichi Sankyo INC. | $24.48 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $20.19 | 2019 | |
| Smith+Nephew, INC. | $20.06 | 2024 | Pico |
| Actelion Pharmaceuticals US, INC. | $18.64 | 2023 | Uptravi |
| Avion Pharmaceuticals | $17.51 | 2020 | |
| Cranial Technologies, INC | $17.43 | 2021 | |
| Coopersurgical, INC. | $15.38 | 2023 | Paragard T 380a |
| Millicent US INC | $14.47 | 2025 | Intrarosa, Femlyv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sedi Hadadian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.